SG Americas Securities LLC Grows Holdings in Biohaven Ltd. $BHVN

SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 291.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,518 shares of the company’s stock after buying an additional 78,585 shares during the quarter. SG Americas Securities LLC owned 0.10% of Biohaven worth $1,191,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BHVN. AQR Capital Management LLC boosted its stake in shares of Biohaven by 49.4% during the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after buying an additional 37,981 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Biohaven by 32.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after buying an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Biohaven by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after acquiring an additional 41,040 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Biohaven by 80.3% in the 1st quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after acquiring an additional 27,433 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Biohaven by 3.3% in the 2nd quarter. Legal & General Group Plc now owns 98,516 shares of the company’s stock valued at $1,390,000 after acquiring an additional 3,152 shares during the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Price Performance

Shares of BHVN opened at $9.28 on Wednesday. The company has a market cap of $1.40 billion, a P/E ratio of -1.33 and a beta of 1.34. The stock has a fifty day moving average price of $10.48 and a 200 day moving average price of $11.70. The company has a debt-to-equity ratio of 4.59, a current ratio of 3.18 and a quick ratio of 3.18. Biohaven Ltd. has a 12 month low of $7.48 and a 12 month high of $24.06.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.21) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.01. On average, research analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BHVN shares. William Blair reiterated a “market perform” rating on shares of Biohaven in a report on Friday, December 26th. Morgan Stanley lowered their price target on Biohaven from $26.00 to $21.00 and set an “overweight” rating for the company in a report on Tuesday, January 6th. Royal Bank Of Canada boosted their price target on Biohaven from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Leerink Partners reiterated an “outperform” rating and issued a $15.00 price target on shares of Biohaven in a report on Tuesday, March 3rd. Finally, The Goldman Sachs Group upgraded Biohaven to a “strong-buy” rating in a report on Friday, February 6th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.64.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.